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Clinical Medicine and Surgery, Federico II UniAbstract Background and aims: The efﬁcacy and safety of lomitapide as adjunct treatment for
adults with homozygous familial hypercholesterolaemia (HoFH) have been conﬁrmed in a phase
3 trial. Given the small number of patients (N Z 29), and variations in patient characteristics,
examining individual cases provides additional details regarding patient management with lomi-
tapide. Here, we examine the details of the Italian patient cohort in the phase 3 trial.
Methods and results: The methodology of the multinational, single-arm, open-label, 78-week,
dose-escalation, phase 3 trial has been previously reported. The current report details the Italian
cohort of six patients (three males, three females) based on individual patient data, individual
patient histories and narratives, and by mean data  SD.
Lomitapide was administered according to the dose-escalation protocol. At Week 78, concen-
trations of low-density lipoprotein-cholesterol were decreased by a mean of 42.6  21.8%
compared with baseline. Lomitapide was similarly well tolerated in the Italian cohort as in the
entire study population. The most common adverse events were gastrointestinal symptoms.
One patient showed an increase in liver transaminases >5 upper limit of normal that resolved
after lomitapide treatment was reduced and maintained at a lower dose.
Conclusion: The efﬁcacy, safety and tolerability of lomitapide demonstrated in the Italian sub-
group of patients are consistent with ﬁndings in the entire study population, and illustrate the
broad applicability of lomitapide therapy across genotypes and clinical phenotypes. These data
also provide an insight into the management of lomitapide use in a cohort of patients within
a clinical trial protocol.
Clinicaltrials.gov Identiﬁer: NCT00730236.
ª 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
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Analysis of HoFH patients treated with lomitapide 37premature atherosclerosis [1,2]. There is considerable
phenotypic variability in HoFH and untreated LDL-C levels
can range from above 13 mmol/L to 3.9 mmol/L [3]. These
phenotypic variations are driven in part by the level
of residual LDL-R activity, governed by the type of
mutation [4].
A recent consensus panel of the European Atheroscle-
rosis Society (EAS) deﬁned treatment guidelines for man-
agement of HoFH. Target LDL-C levels are <2.5 mmol/L in
adults and <1.8 mmol/L in adults with clinical cardiovas-
cular disease [4]. Effective therapies are required to meet
these stringent targets; however, due to impaired LDLR
activity in HoFH, standard lipid-lowering therapies (LLTs)
that rely on functional LDLR (such as statins) are not suf-
ﬁciently effective in HoFH.
Lomitapide is an oral small-molecule inhibitor of the
microsomal triglyceride transfer protein (MTP) that has
been approved as an adjunct to lipid-lowering treatment,
with or without lipoprotein apheresis, in adults with HoFH
[5,6]. Lomitapide reduces plasma LDL-C by directly and
selectively inhibiting MTP e a protein that facilitates as-
sembly of apolipoprotein B-containing lipoproteins in the
liver and intestine e leading to reductions in lipoprotein
secretion and circulating lipoprotein-borne lipids,
including cholesterol and triglycerides [6].
The efﬁcacy and safety proﬁle of lomitapide as an
adjunct treatment in adults with HoFH was conﬁrmed in a
multinational, single-arm, open-label, 78-week, phase 3
trial [7]. In that trial, lomitapide in combination with other
LLTs was effective in lowering LDL-C irrespective of
concomitant lipoprotein apheresis therapy [7]. Throughout
the study, lomitapide exhibited a clinically manageable
safety proﬁle. The most common adverse events (AEs)
were gastrointestinal (GI). Four patients (17%) had
aminotransferase elevations >5 upper limit of normal
(ULN), e all were managed by dose reduction or inter-
ruption [7]. In an open-label extension, lomitapide efﬁcacy
was maintained to 126 weeks (primary endpoint), and no
new safety signals emerged during long-term follow-up
(4.5 years) [8].
Due to variation in patients characteristics, including
drug tolerability, the clinical trial protocol required an
individualised dosing and treatment plan. Given the
relatively small number of patients in the trial (N Z 29)
[7], it is interesting to evaluate how cases were
managed, and how efﬁcacy and safety outcomes varied
according to tailored treatment, as information of this
type can be used to inform treatment decisions in real-
world clinical practice. We examined the efﬁcacy and
safety of lomitapide in each of the six Italian patients
enrolled in the phase 3 trial; thus, providing practical
insights into the management of HoFH patients with this
therapy.
Patients and methods
The design of the main phase 3 trial has been reported
previously [7]. Brieﬂy, this 78-week, single-arm, dose-
escalation study of lomitapide (5e60 mg) consisted ofthree phases: a minimum 6-week run-in phase followed by
a 26-week efﬁcacy phase, and then a 52-week safety phase.
The primary efﬁcacy endpoint was mean percent change
from baseline in LDL-C at 26 weeks. During the efﬁcacy
phase, the dose of lomitapide was escalated based on
safety/tolerability. Background LLTs (including lipoprotein
apheresis) were to remain constant during the efﬁcacy
phase, but could be altered during the safety phase [7]. The
individualised dose of lomitapide remained constant at the
maximum tolerated dose established in the efﬁcacy phase,
unless pre-speciﬁed dosing rules mandated dose modiﬁ-
cation. At the conclusion of the safety phase, patients
could enter a long-term extension. Safety endpoints
included assessment of hepatic fat, as measured by nuclear
magnetic resonance spectroscopy (NMRS), liver function
tests, and AEs [8].
Patients were counselled by a nutritionist at their ﬁrst
study visit. All were provided with information on how to
adopt a diet of <20% energy from fat, and patients were
advised to observe associations between GI adverse events
and types of foods consumed.
For conﬁrmed elevations in alanine transaminase (ALT)
or aspartate transaminase (AST) 5.0e9.9ULN, or>100 U/L
but <200 U/L above the baseline value if abnormal, the
lomitapide dosewas reduced,with the option to re-escalate
once elevations resolved to <3ULN [7]. If patients
reached AST/ALT elevations >10ULN, the drug was
temporarily discontinued while probable causes were
investigated and therapy could be re-started once the LFTs
were <3ULN.
Hepatic fat was measured non-invasively using NMRS
imaging, or (if NMRS was contraindicated) computed to-
mography (CT) or ultrasound scanning.
The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and International
Conference on Harmonization Good Clinical Practice
guidelines. Approval was obtained from the ethics com-
mittee or institutional review board at each participating
centre. Written informed consent was received from all
patients.
Results
Patients
Three male and three female HoFH patients (diagnosed
according to clinical and genetic criteria) were enrolled in
four Lipid Clinics across Italy. Baseline patient character-
istics, including genotypes, are summarised in Table 1. In
addition to LLTs, four patients were on lipoprotein apher-
esis therapy conducted according to local clinical practice,
patient requirements and physician discretion.
All patients were established as homozygotes or com-
pound heterozygotes for mutations in the LDLR gene or
genes affecting LDL-R functionality (Table 1). Patient 1,
Patient 2, Patient 1 and Patient 2 were compound het-
erozygotes for LDLR mutations. Patient 3 was a true ho-
mozygote for a recessive form of familial hypercholes
terolaemia (i.e., autosomal recessive hypercholestero
Table 1 Baseline characteristics of the Italian cohort in the phase 3 study of lomitapide in patients with homozygous familial
hypercholesterolaemia
Patient
identiﬁer
Diagnosis
of HoFH
Allelic
mutations
Age/
Gender
Medical history of
cardiovascular diseases
Baseline
LDL-C
(mg/dL)
Lipoprotein
apheresis, Yes/No
(Frequency)
Background
lipid-lowering
therapy
BMI
(kg/m2)
aPatient 1 Clinical, genetic p. A512T
p. G571E
19 years/
Female
Hypertension, carotid
atherosclerosis
determined via carotid
ultrasound examination
181.2 Yes
(every 42 days)b
Statin,
ezetimibe
27.1
aPatient 2 Clinical, genetic,
skin ﬁbroblast
Del exons
13e15
p. C343R
23 years/
Male
Generalised
atherosclerosis
(coronary, carotid and
renal arteries) since age
7 years (determined via
coronary
catheterisation).
Regression of a stenosis
in the anterior
descending aorta while
undergoing lipoprotein
apheresis.
396.2 Yes (weekly) Statin,
ezetimibe
21.5
aPatient 3 Clinical, genetic
(LDLRAP1)
c.431InsA;H114Q
fs X26
c.431InsA;H114Q
fs X26
45 years/
Male
Early onset arterial
disease since age 8
years; transient
ischaemic attack (42
years); double coronary
artery bypass graft (43
years)
357.1 Yes (bi-weekly) Statin,
ezetimibe
28.7
aPatient 4 Clinical, genetic,
skin ﬁbroblast
p. C68R
p. G571E
18 years/
Female
Absent (determined via
coronary
catheterisation)
165.7 No Statin,
ezetimibe,
fenoﬁbrate
19.3
aPatient 5 Clinical, genetic p. C358R
p. A378 T
19 years/
Female
Carotid atherosclerosis
since age 17 years
(determined via B-
mode ultrasound)
476.8 No Atorvastatin 20.6
aPatient 6 Genetic, clinical,
skin ﬁbroblast
p. C331W
p. C331W
26 years/
Male
Absent (determined via
coronary and aortic
catheterisation)
216.4 Yes (weekly) Statin,
ezetimibe
21.0
LDL-C, low-density lipoprotein-cholesterol; BMI, body mass index.
a Patient 1 and Patient 2 were patients enrolled in the Palermo study site; Patient 3 and Patient 4 were patients enrolled in the Milan site;
Patient 5 was a patient enrolled in the Ferrara site; Patient 6 was a patient enrolled in the Rome site. Patient 2 and Patient 4 were formerly treated
in Rome and later moved to Palermo and Milan.
b This schedule may not have been effective, and therefore the efﬁcacy of apheresis in this patient may be low. The schedule was selected
according to patient preference.
38 M. Averna et al.laemia [ARH]) carrying the ARH7 mutation in the LDL-R
adapter protein-1 (LDLRAP1) gene [9]. Patient 6 carried
two unclassiﬁed mutations.
All six patients completed the pivotal trial according to
the study protocol (Week 78). Five patients entered the
extension study and were ongoing (receiving study drug
and undergoing safety monitoring beyond Week 126) at
the time of this analysis.
Treatment
Concomitant medications are shown in Table 1. Four
patients underwent regular lipoprotein apheresis with a
frequency that ranged from weekly to biweekly. One
patient (Patient 1), according to stated preference and
against established recommendations, received apheresis
once every approximately six weeks throughout the
study. Despite intensive LLT, LDL-C levels were consid-
erably elevated at baseline (range: 4.7e12.3 mmol/L) andfar above recommended EAS target levels for HoFH
[4,10].
Maximum tolerated dose of lomitapide ranged from
5 mg to 60 mg (mean 40 mg) in the efﬁcacy and safety
phases. These doses were maintained in the extension
phase.Efﬁcacy
Individual, absolute and percent changes in LDL-C levels
are shown in Fig. 1A/B. At Week 26, LDL-C concentration
had decreased by 50% compared with baseline in ﬁve
patients, and by 29% in the remaining patient (Patient 5).
The mean decrease for all six patients was 50.9  13.0%
at Week 26 (last observation carried forward),
66.3  14.5% at Week 56, and 40.1  27.7% at Week 78
for the ﬁve patients remaining on drug. Lomitapide efﬁ-
cacy was maintained in the extension study cohort (nZ 5)
Figure 1 Effects of lomitapide on LDL-C and other lipids. (A) Individual baseline LDL-C levels. (B) Percent changes from baseline in LDL-C. (C) Mean
changes in lipid parameters; *no Week 78 data.
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(n Z 5).
By Week 78, concentrations of LDL-C in two patients
had decreased by >60% compared with baseline (Patient 1
and 2) and by 30e46% in three patients (Patient 4, 5 and 6)
(Fig. 1). At Week 126 (extension study), decreases from
baseline for Patient 1, 2, 5 and 6 were sustained (86%,
73%, 52%, and 25%, respectively). Although LDL-C
values for Patient 4 showed a 31% increase from baseline
at Week 126, by Week 138 this had become a 47%
decrease.
Mean values for other lipid values (total cholesterol,
high-density lipoprotein-cholesterol [HDL-C], triglycerides
and non-HDL-C) during the 78 weeks are shown in Fig. 1C.
Mean levels of non-HDL-C and total cholesterol tracked
LDL-C levels closely. HDL-C levels were not affected by
lomitapide, and triglyceride levels underwent a modest
reduction (15%).
GI side effects
No serious GI AEs were reported for these patients during
the efﬁcacy, safety or extension phases. The most
commonly reported GI events in this subgroup (diarrhoea,
nausea, abdominal distension, constipation, ﬂatulence,
rectal tenesmus) were assessed to be mild-to-moderate in
intensity in all but one patient. Patient 6 experienced
worsening diarrhoea when the lomitapide dose was
escalated to 60 mg/day at Week 14. Lomitapide was dis-
continued for 6 days at Day 128 due to non-serious diar-
rhoea (thought to be attributable to lomitapide) and
restarted at 60 mg/day without further severe GIFigure 2 Number and intensity osymptoms. Mean BMI of the six patients decreased from
23.0  3.9 m2/kg to 21.9  1.32 m2/kg, and was not
excessively out of range for any patient [Table 1].
Although patients had been trained to limit their total
fat intake to <20% of total calories, the mean percent of fat
intake was above the suggested threshold (27% at baseline,
29% at Week 78). Nevertheless, the incidence and intensity
of side effects decreased during the efﬁcacy and safety
phases (Fig. 2) regardless of lomitapide dose.
Hepatic side effects
Five patients experienced no elevations in LFTs of >3ULN
during either the efﬁcacy or safety phases (Fig. 3A/B). The
sixth patient (Patient 3) had elevations of ALT and AST of
>5ULN (Fig. 3C). In this patient, liver enzyme levels rose
just after escalation of lomitapide dose from 5 mg to
10 mg, and reached a peak soon after starting 20 mg. The
dose was reduced promptly to 10 mg and then to 5 mg.
The AST and ALT levels fell to within normal limits and the
patient remained on a dose of 5 mg for the duration of the
study. During the long-term extension trial, four of the ﬁve
patients did not experience elevations in ALT or AST
3ULN. Patient 1 had an elevation between 3 and
5ULN at Week 114, which resolved without dose
adjustment.
Mean hepatic fat was 1% (range: 0.49%e2.67%) at
baseline, 6.2% (3%e19%) at Week 26, 12.35% (4.3%e37.7%)
at Week 56, and 10.8% (5.8%e19%) at Week 78 (Fig. 3D). For
Patient 3 (who showed increased AST and ALT levels
>5ULN), hepatic fat content increased up to 37.72% at
Week 56. This patient stopped treatment at Week 66 andf gastrointestinal side effects.
Figure 3 Hepatic effects of lomitapide. (A and B) Individual transaminase levels in patients who did not meet the criteria for reduction of lomi-
tapide dose (A: ALT and B: AST). (C) Adjustment of lomitapide dose in response to transaminase elevations >5ULN in Patient 3. (D) Individual
percent hepatic fat content (by NMRS).
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on MRI. At Week 84 (18 weeks after treatment cessation)
his fat levels had decreased to 7%e15% as determined by
CT scan. At Week 126, mean hepatic fat in the ﬁve patients
who had continued in the extension phase was 16.2  7.5%
(range: 4.8%e24.7%).
Aside from Patient 3, hepatic fat continued to rise
steadily in four patients (maximum 19% in Patient 1),
while remaining steady for Patient 5 (Weeks 26, 56 and
78: 4.9%, 9.3%, 6.5%).Concomitant lipoprotein apheresis therapy
Four patients (Patient 1, Patient 2, Patient 3, Patient 6)
received lipoprotein apheresis at baseline. Three of these
received apheresis every one to two weeks, while the
fourth (Patient 1) received suboptimal apheresis therapy
once every six weeks. All patients were required to be
stable during the run-in period and efﬁcacy phase. For two
patients (Patient 1, Patient 2) who reached LDL-C levels
<2.5 mmol/L at Weeks 26 and 36, respectively, the deci-
sion was made to stop apheresis. As the mean interval
LDL-C levels were signiﬁcantly lower than those before
lomitapide treatment and during the efﬁcacy phase,
apheresis treatment was discontinued permanently
(Fig. 4). Cardiac follow-up of these two patients conﬁrmed
no new or worsened cardiac AEs related to therapy. In
addition, one patient (Patient 6) increased the time in-
terval between apheresis treatments permanently at
wWeek 34 during the safety phase. No additionalFigure 4 Changes in levels of LDL-C before and aftemodiﬁcations to apheresis treatment occurred during the
extension trial.
Discussion
The Italian patients described in this analysis represent a
broad range of HoFH patients based on gender, use of
concomitant lipoprotein apheresis, baseline LDL-C, car-
diovascular disease proﬁle, and an assortment of under-
lying mutations with varying receptor functionality. By
focussing on this subset of patients, we can not only learn
about individual patient management in the clinical trial
setting, but also understand how the varying clinical pre-
sentation and therapeutic responses that characterise
HoFH can be handled on a case-by-case basis, thereby
informing real-world management of the disease.
The overall efﬁcacy and safety of lomitapide in this
subgroup was consistent with that seen in the full study
population [7]. At Week 26, LDL-C concentration had
decreased by z50% compared with baseline in ﬁve pa-
tients, and by 29% in one patient (Patient 5). At Week 78, in
5 of 6 patients, LDL-C concentrations were decreased by
30% to >60% compared with baseline [7].
Responses between patients were variable, and this is to
be expected for two reasons. Firstly, HoFH is a rare disease,
therefore the limited patient samples introduced inherent
variability that may be less evident with greater patient
numbers. Secondly, as of 2011 there are upwards of 1700
identiﬁed mutations in the LDLR, 39 in LDLRAP1 and a
further 163 in PCSK9 [11]. The extensive genotypic variance
in HoFH is accompanied by variable phenotype, includingr stopping apheresis (A: Patient 1; B: Patient 2).
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reasonable that variations in response to lomitapidemay be
due to differences in genetic and phenotypic proﬁle that
have the potential to affect not only efﬁcacy, but also the
most tolerated dose of lomitapide for each individual as
determined by the trial protocol. Notably, Patient 3, the
only patient in the cohort with mutations in LDLRAP1,
achieved an LDL-C reduction of 51% at Week 26 with a
lomitapide dose of only 5 mg/day. Whether this response
pattern is related to mutation type, is not known but it will
be interesting to observe how other patients with LDLRAP1
mutations respond to lomitapide.
Analysis of the Italian cohort from the phase 3 trial
indicated an upturn in mean LDL-C levels from Weeks
56e78, suggesting a decrease in efﬁcacy. However, indi-
vidual responses were highly variable and patient sample
size was small. In the total trial population, mean LDL-C
levels remained stable over the same period [7], which
remained stable in the long-term extension phase of the
trial (to Week 126) [8]. Apparent variability in the Italian
cohort highlights the problems inherent in making con-
clusions based on mean data from small sample sizes.
Side effects associated with lomitapide were similar to
those recorded in the entire study population [7]. The
most common AEs were GI symptoms: diarrhoea, nausea,
vomiting, dyspepsia, and abdominal pain.
The lomitapide treatment protocol is important to
achieve a maximal tolerable dose, and subsequent
maximal reduction in LDL-C. In particular, patients in the
trial were instructed to follow a strict low-fat diet of
<20% of the total calories from dietary fat and con-
sumption of 1 alcoholic drink/day for women and 2
drinks/day for men; although any use of alcohol during
lomitapide treatment is not recommended [6]. Only one
Italian patient (Patient 3) showed an increase of trans-
aminases >5ULN at the Week-6 evaluation, shortly after
escalation of lomitapide from 10 mg to 20 mg. The
percent LDL-C reduction (9.7%) was also considerably
less in this patient than that for the remainder of the
cohort at Week 78. This subject’s reported alcohol con-
sumption was 7e10 drinks per week, and this was
believed to be a major contributing factor in the
lomitapide-induced increases in ALT and AST e the pa-
tient was not receiving any other medications extensively
metabolised via CYP3A4. Similarly, in the full phase 3 trial
population, three of the four patients who had ALT ele-
vations >5ULN reported consumption of alcohol in
quantities greater than those recommended in the pro-
tocol [7]. After an initial dose reduction back to 10 mg,
and a further reduction to 5 mg, the patient in the Italian
subgroup was able to remain on the lower dose of 5 mg/
day for the remainder of the study.
Accumulation of liver fat is intrinsically linked to the
mechanism of action of MTP inhibitors [12]. Average
accumulation of hepatic fat for the Italian subgroup was
consistent with that reported in the entire trial population.
Notably, the same patient who had transaminase eleva-
tions >5ULN also showed a signiﬁcant increase in NMRS-
measured fat accumulation. After an initial rise, medianhepatic fat levels appeared to increase at a slower pace.
The mechanisms underlying the increase and the long-
term implications of hepatic fat accumulation in patients
treated with MTP inhibitors remain to be determined, and
are being investigated further in the LOWER registry of
patients receiving lomitapide.
Of interest, although the clinical trial protocol
mandated a total fat intake <20% of total calories, the
actual percent fat intake estimated from the diet logs was
higher than advised (23%e26% for the full population;
27%e29% for the Italian cohort). These observations sug-
gest that with continued treatment with MTP inhibition,
an unknown adaptive mechanism may play a part in the
improved tolerance to dietary fat.
Other concomitant LLTs (including lipoprotein apher-
esis) could be modiﬁed during the safety phase according
to physician discretion if certain criteria were met. For
example, two Italian patients discontinued apheresis
treatment and one patient increased the treatment inter-
val. The decision to stop was made by the treating physi-
cian and based on LDL-C levels being close to the EAS-
recommended target [10]. Notably, Patient 2 discontinued
long-term, weekly apheresis monotherapy, during which
regression of a stenosis in the anterior descending aorta
was evident upon coronary angiography. There was no
stenosis present by June 2013. This regression was not
evident in the other patient who stopped apheresis (Pa-
tient 1). Regression of stenosis with apheresis has been
reported previously [13]. The beneﬁts of apheresis addi-
tion to LDL-C lowering (including clearance of Lp(a))
[14e16] should not be underestimated. However, apher-
esis can be a time-consuming process and place a
considerable burden on patients [17]. New therapeutic
options that may allow a modiﬁed apheresis schedule may
be welcomed by some patients and their families.
The current analysis illustrates the broad applicability
of lomitapide therapy across varying clinical phenotypes.
For example, Patient 1 and Patient 2 had different under-
lying genetic mutations (Table 1) and commenced with
LDL-C levels of 181.2 mg/dL (4.7 mmol/L) and 396.2 mg/dL
(10.2 mmol/L), respectively. Both were receiving lipopro-
tein apheresis and background LLT comprising a statin plus
ezetimibe. Despite differing phenotypes and genotypes,
both patients achieved >50% reduction in LDL-C by Week
26 while receiving lomitapide. Both patients stopped
apheresis (Weeks 26 and 36, respectively) with no impact
on lipid control. At Week 78, the LDL-C values for Patient 1
and Patient 2 were 1.8 mmol/L and 3.0 mmol/L, respec-
tively. Notably, Patient 1 was receiving apheresis once
every 42 days. Given the established rebound character-
istics of LDL-C, whereby LDL-C levels return to pre-
apheresis levels within 1e2 weeks [18], it is likely that
the apheresis in this patient was not contributing much if
anything to the observed decreases in LDL-C. Therefore, in
Patient 1, decreases in LDL-C over and above statins and
ezetimibe may be due solely to lomitapide. This also un-
derscores the variability in individual response.
In conclusion, despite different clinical presentations of
HoFH, the efﬁcacy, safety and tolerability of lomitapide
44 M. Averna et al.demonstrated in the Italian subgroup of patients are
consistent with ﬁndings in the overall phase 3 study
population. LDL-C levels were signiﬁcantly reduced
following initiation of lomitapide therapy in all patients.
This subgroup analysis highlights how individualised pa-
tient management compliant with the treatment protocol
can be used to achieve meaningful and tolerable reduction
in LDL-C. The efﬁcacy and safety of lomitapide in individ-
ual patients will be informed further by data emerging
from the real-world clinical use of lomitapide. To date,
w500 patients have received the drug, and lomitapide is
subject to a pharmacovigilance programme that includes a
registry (Lomitapide World-wide Effectiveness Registry
[LOWER]), the data from which will further inform real-
world clinical use of the drug [19].
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